Stock listing

Stuttgart:PBS0 Precision BioSciences, Inc. Aktie

German listing (Stuttgart) of Precision BioSciences, Inc. · home listing NASDAQ:DTIL

Follow Precision BioSciences, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:DTIL

$7.40 USD +0.30 (+4.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:DTIL

Past year +48.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.77 – $7.55 USDNov 20, 2026
Volume
429,792 sharesNov 20, 2026
Market cap
$282.5M USDAt the close on Nov 20, 2026 · price × 38.17M shares outstanding
52-week range
$3.53 – $11.29 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.52M USDMedian day 251,718 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Precision BioSciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DTIL · Home$7.40 USD+0.30 (+4.2%)429,792$6.77$7.55$6.77$7.10Close on Nov 20, 2026
Frankfurt:PBS0€5.76 EUR-0.24 (-4.0%)—€6.19€6.19€5.76€6.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DTIL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.40+0.30+4.2%$6.77$7.55$6.77429,792
$7.10+0.05+0.7%$6.94$7.39$6.94370,311
$7.05-0.23-3.2%$7.26$7.46$6.88350,990
$7.28-0.285-3.8%$7.52$7.635$7.25204,411
$7.565-0.475-5.9%$8.15$8.16$7.525394,619
$8.04-1.11-12.1%$8.97$9.00$7.972414,048
$9.15-0.35-3.7%$9.46$9.585$8.93251,718
$9.50-0.18-1.9%$9.57$10.02$9.22352,757
$9.68-0.92-8.7%$10.72$10.80$9.615589,692
$10.60+0.73+7.4%$9.80$10.78$9.071,228,661
$9.87+1.75+21.6%$8.49$11.29$8.402,911,977
$8.12+1.15+16.5%$7.205$8.13$7.14400,518
$6.97+0.02+0.3%$6.95$7.186$6.64144,825
$6.95-0.11-1.6%$7.06$7.42$6.82167,793
$7.06-0.38-5.1%$7.31$7.42$6.98108,829
$7.44-0.03-0.4%$7.50$7.82$7.37165,713
$7.47+0.68+10.0%$6.76$7.50$6.66189,294
$6.79+0.38+5.9%$6.39$6.81$6.29164,247
$6.41-0.23-3.5%$6.68$6.876$6.37266,677
$6.64-0.14-2.1%$6.73$6.73$6.29275,388
$6.78+0.07+1.0%$6.70$6.925$6.58132,428
$6.71+0.15+2.3%$6.62$6.86$6.545231,040
$6.56+0.37+6.0%$6.09$6.67$6.09213,655
$6.19+0.42+7.3%$5.80$6.21$5.77176,469
$5.77-0.40-6.5%$6.18$6.18$5.72300,200
$6.17+0.14+2.3%$6.04$6.20$5.98246,100
$6.03-0.07-1.1%$6.05$6.25$5.92294,200
$6.10-0.43-6.6%$6.51$6.55$6.05326,700
$6.53-0.19-2.8%$6.71$6.729$6.448228,800
$6.72+0.29+4.5%$6.43$6.92$6.35263,700
$6.43+0.18+2.9%$6.25$6.53$6.19332,500
$6.25+0.05+0.8%$6.20$6.38$6.11162,500
$6.20-0.11-1.7%$6.36$6.40$6.105191,000
$6.310.000.0%$6.36$6.375$5.975218,800
$6.31-0.02-0.3%$6.42$6.44$6.20293,000
$6.33+0.07+1.1%$6.33$6.47$6.24242,200
$6.26+0.08+1.3%$6.24$6.40$6.14249,200
$6.18-0.06-1.0%$6.37$6.45$6.08154,100
$6.24+0.02+0.3%$6.21$6.255$6.00222,800
$6.22-0.11-1.7%$6.35$6.55$6.18204,000
$6.33-0.03-0.5%$6.31$6.465$6.18401,800
$6.36-0.83-11.5%$7.16$7.17$6.34355,900
$7.19+0.69+10.6%$6.57$7.313$6.55431,600
$6.50-0.17-2.5%$6.73$6.75$6.44272,300
$6.670.000.0%$6.65$6.87$6.57240,400
$6.67+0.04+0.6%$6.77$6.923$6.41373,900
$6.63+0.02+0.3%$6.65$6.82$6.53289,200
$6.61-0.25-3.6%$6.86$6.90$6.48314,600
$6.86-0.31-4.3%$7.13$7.255$6.85236,300
$7.17-0.07-1.0%$7.28$7.38$7.06191,400
$7.24-0.01-0.1%$7.16$7.27$7.035143,400
$7.25-0.15-2.0%$7.38$7.49$7.15273,500
$7.40-0.07-0.9%$7.41$7.49$7.20139,900
$7.47+0.10+1.4%$7.32$7.575$7.32124,200
$7.37-0.08-1.1%$7.48$7.55$7.23187,000
$7.45-0.19-2.5%$7.66$7.82$7.24358,900
$7.640.000.0%$7.54$7.68$7.49170,900
$7.64-0.14-1.8%$7.75$7.80$7.493214,800
$7.78-0.62-7.4%$8.37$8.43$7.72222,300
$8.40-0.09-1.1%$8.54$8.54$8.21274,800
$8.49-0.06-0.7%$8.58$8.66$8.33262,700
$8.55+0.10+1.2%$8.43$8.75$8.33418,200
$8.45-0.40-4.5%$8.82$8.82$8.36232,700
$8.85+0.13+1.5%$8.81$9.08$8.63305,200
$8.72+0.22+2.6%$8.60$9.34$8.59496,300

Splits

1 split · NASDAQ:DTIL · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
Stuttgart:PBS0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

All Precision BioSciences, Inc. news

Precision BioSciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 199 in all · newest Nov 20, 2026 · oldest 2019
Decks
54 decks · latest Nov 5, 2026

Where Precision BioSciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:DTIL · Home listingNASDAQUnited StatesUSD
gettex:PBS0gettexGermanyEUR
LS Exchange:A400ASLS ExchangeGermanyEUR
Lang & Schwarz:A400ASLang & SchwarzGermanyEUR
Stuttgart:PBS0 · This pageStuttgartGermanyEUR
BOATS:DTILBOATSUnited StatesUSD
Frankfurt:PBS0FrankfurtGermanyEUR
Dusseldorf:PBS0DusseldorfGermanyEUR
Hamburg:PBS0HamburgGermanyEUR
Munich:PBS0MunichGermanyEUR
Tradegate:PBS0TradegateGermanyEUR

Valuation

EV/sales 5.1× against a median of 467×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$228.3M USD
P/E
Loss
EV/sales
5.1×
EV/EBITDA
Negative EBITDA
Price/book
5.5×
Gross margin
Not reported
Operating margin
−80.3%
Net margin
−85.6%
Debt to equity
0.5×
Beta vs S&P 500
0.30

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Precision BioSciences, Inc. · NASDAQ:DTILUS$282.5MUS$228.3Mn/a5.1×n/a5.5×−85.6%0.5×0.30
Contineum Therapeutics, Inc. · NASDAQ:CTNMUS$286.1MUS$47.86Mn/an/an/a1.2×n/a0.0×1.53
TRex Bio, Inc. · NASDAQ:TRXBUS$283.1MUS$205.0Mn/an/an/an/an/an/an/a
Greenwich LifeSciences, Inc. · NASDAQ:GLSIUS$282.6MUS$276.7Mn/an/an/an/an/an/a2.80
AP Biosciences, Inc. · TPEX:6945US$282.3MUS$215.7Mn/an/an/a4.0×n/a0.0×n/a
Fulcrum Therapeutics, Inc. · NASDAQ:FULCUS$281.8M−US$17.87Mn/an/an/a0.9×n/a0.0×0.42
Circio Holding ASA · OSL:CRNAUS$281.0MUS$225.8Mn/an/an/a5.3×n/a0.0×n/a
Relmada Therapeutics, Inc. · NASDAQ:RLMDUS$279.5MUS$77.42Mn/an/an/a1.4×n/a0.0×1.57
Benitec Biopharma Inc. · NASDAQ:BNTCUS$276.1MUS$99.78Mn/an/an/a1.6×n/a0.0×1.46
Galectin Therapeutics Inc. · NASDAQ:GALTUS$271.4MUS$293.0Mn/an/an/an/an/an/a1.20
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.2MUS$182.6Mn/a467×n/a3.3×n/a0.0×n/a
Median of the othersUS$281.4MUS$193.8M467×1.6×0.0×1.50

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
29.40 USD · Analysts' mean
EPS, year to Dec 2026
-2.85 · 4 analysts
Revenue, year to Dec 2026
11.35M · 5 analysts

Team and board

Officers

OfficerRole
Michael AmorosoPresident, Chief Executive Officer
Naresh TannaChief Financial Officer
Alex KellyChief Operating Officer
Dario ScimecaChief Legal Officer
Neil LeatherburySenior Vice President of Chemistry, Manufacturing, and Controls (CMC)
Cassie GorsuchChief Scientific Officer
Cindy AtwellChief Development Officer
Jeff SmithChief Research Officer
Juli BlancheChief People Officer
Mark SulkowskiHead Clinical Development Advisor

Events

QuarterResultsShare move
Q3 2026Nov 3, 2026 · Before open+0.3%
Q2 2026Aug 6, 2026 · Before open−0.7%
Q1 2026May 5, 2026 · Before open−2.4%
Q4 2025Mar 12, 2026+12.1%
Q3 2025Nov 3, 2025 · Before open−9.8%
Q2 2025Aug 7, 2025 · Before open−5.0%
Q1 2025May 15, 2025 · Before open−8.1%
Q4 2024Mar 25, 2025 · Before open−9.8%
Q3 2024Nov 4, 2024 · Before open−8.1%
Q2 2024Aug 1, 2024 · Before open+0.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open+8.1%
Q4 2023Mar 27, 2024 · Before open+1.8%
Q3 2023Nov 7, 2023 · Before open−2.5%
Q2 2023Aug 4, 2023 · Before open+3.9%
Q1 2023May 9, 2023 · Before open0.0%
Q4 2022Mar 9, 2023 · Before open−11.3%
Q3 2022Nov 8, 2022 · Before open+2.4%
Q2 2022Aug 8, 2022 · Before open−7.5%
Q1 2022May 9, 2022 · Before open−9.8%
Q4 2021Mar 15, 2022 · Before open−16.4%

Open Events

Decks

DeckKindSlidesDate
AASLD 2026Conference74 slidesNov 5, 2026
Investor Presentation (November 2026)Investor deck76 slidesNovember 2026
Investor Presentation (August 2026)Investor deck53 slidesAugust 2026
Technical Presentation (May 2026)Technical58 slidesMay 27, 2026
Corporate Update (March 2026)Corporate update45 slidesMar 17, 2026
Investor Presentation (January 2026)Investor deck33 slidesJanuary 2026
AASLD 2025Conference19 slidesNov 10, 2025
Corporate Update (November 2025)Corporate update43 slidesNovember 2025
Investor Presentation (September 2025)Investor deck44 slidesSeptember 2025
Investor Presentation (May 2025)Investor deck56 slidesMay 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (May 2025)Investor deck55 slidesMay 2025
ASGCT 2025Conference21 slidesMay 2025
Corporate Update (May 2025)Corporate update38 slidesMay 2025
Global Hepatitis Summit 2025Conference19 slidesMar 18, 2025
Investor Presentation (January 2025)Investor deck39 slidesJanuary 2025
Investor Presentation (November 2024)Investor deck53 slidesNov 15, 2024
Investor Presentation (November 2024)Investor deck40 slidesNovember 2024
Investor Presentation (October 2024)Investor deck40 slidesOctober 2024
Investor Presentation (August 2024)Investor deck40 slidesAugust 2024
UMDF 2024Conference37 slidesJun 27, 2024
Investor Presentation (June 2024)Investor deck54 slidesJune 2024
Corporate Update (April 2024)Corporate update19 slidesApril 2024
Investor Presentation (January 2024)Investor deck77 slidesJan 12, 2024
American Association for the Study of Liver Disease (AASLD) 2023Conference32 slidesNov 13, 2023
Investor Day (September 2023)Investor day111 slidesSep 12, 2023
Investor Presentation (August 2023)Investor deck36 slidesAugust 2023
EASL (June 2023)Conference18 slidesJun 22, 2023
American Society of Gene and Cell Therapy 2023, Late-Breaking Abstracts 2Conference16 slidesMay 19, 2023
Investor Presentation (May 2023)Investor deck68 slidesMay 2023
Global Hepatitis Summit 2023Conference17 slidesApr 26, 2023
H.C. Wainwright Cell Therapy Virtual Conference 2023Conference47 slidesFebruary 2023
Investor Presentation (January 2023)Investor deck52 slidesJanuary 2023
ESGCT 2022Conference19 slidesNov 8, 2022
Investor Presentation (November 2022)Investor deck41 slidesNovember 2022
Investor Presentation (August 2022)Investor deck40 slidesAugust 2022
Merger or Acquisition (June 2022)Merger or acquisition24 slidesJun 22, 2022
Corporate Update (June 2022)Corporate update33 slidesJun 8, 2022
Investor Presentation (May 2022)Investor deck30 slidesMay 2022
Investor Presentation (April 2022)Investor deck30 slidesApril 2022
40th J.P. Morgan Health Care Conference (January 2022)Conference27 slidesJan 12, 2022
Investor Presentation (January 2022)Investor deck34 slidesJan 11, 2022
2021 ASH (American Society of Hematology) Annual MeetingConference36 slidesDec 11, 2021
Investor Day (September 2021)Investor day76 slidesSep 9, 2021
Investor Presentation (July 2021)Investor deck31 slidesJuly 2021
Investor Presentation (January 2021)Investor deck35 slidesJanuary 2021
Investor Presentation (November 2020)Investor deck28 slidesNovember 2020
Investor Presentation (June 2020)Investor deck27 slidesJun 2, 2020
Investor Presentation (April 2020)Investor deck28 slidesApril 2020
Investor Presentation (January 2020)Investor deck34 slidesJan 15, 2020
Investor Presentation (January 2020)Investor deck33 slidesJanuary 2020

This page holds 50 of 54 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$125M · US$7.75 a share · TD Cowen +1
Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead)
Buyers: First Light Asset Management; MPM BioImpact; Bleichroeder LP; Lynx1 Capital Management; Readout Capital; Aberdeen Investments; Driehaus Capital Management
Use of proceeds: Continued research and development of PBGENE-HBV and PBGENE-DMD, working capital and general corporate purposes
Nov 5, 2026
Strategic investment of common stock
Announced: US$2.25M · US$11.17 a share
Buyers: TG Therapeutics, Inc. ($2.25 million for 201,504 shares of common stock at $11.17 per share)
Use of proceeds: Supports cash runway through 2028 and focus on in vivo gene editing pipeline
Mar 2, 2026
Public offering of common stock, pre-funded warrants and warrants
Announced: about US$75M · US$6.14 a share · ½ warrant at US$7.25 for 60 months · Guggenheim Securities
Dealers: Guggenheim Securities (lead)
Buyers: Aberdeen Investments; Bleichroeder LP; Driehaus Capital Management; Empery Asset Management LP; Lynx1 Capital Management; Octagon Capital; Readout Capital; Sphera Funds Management; Stonepine Capital Management
Use of proceeds: Ongoing and planned research and development, working capital and general corporate purposes
Nov 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Mar 27, 2019.

Price
US$16.00 a share
Shares offered
7,900,000 shares of common stock
Offering size
US$126.4 million
Underwriters' option
Up to 1,185,000 more shares
Underwriters
J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, Barclays · In the order on the cover
Shares delivered
On or about Apr 1, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceOct 19, 2018
Filed publiclyMar 1, 2019
Amended twiceNewest Mar 18, 2019
Shares registered with an exchangeMar 19, 2019
Declared effective by the SECMar 27, 2019
Final prospectus, with the priceMar 28, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Mar 28, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue34.3M68.7M48.7M25.1M115.5M24.3M1.07B10.9M6.48M7.01M
Cost of revenue2.75M4.58M8.26M9.00M000
Gross profit34.3M68.7M48.7M25.1M115.5M24.3M22.2M10.9M6.48M7.01M
Research and development54.2M59.6M53.4M46.1M115.2M98.1M82.4M45.1M20.3M9.10M
Selling, general and administrative32.2M35.3M39.1M41.3M39.7M36.1M27.0M13.7M8.02M6.17M
Operating income-52.1M-26.2M-43.7M-62.3M-39.4M-109.8M-87.2M-47.9M-22.0M-8.83M
Depreciation and amortization1.47M3.40M6.82M7.80M8.98M8.78M5.32M2.35M1.44M640.0K
EBITDA-50.7M-22.8M-36.9M-54.5M-30.4M-101.1M-81.9M-45.6M-20.5M-8.19M
Interest expense1.42M1.78M2.23M1.11M132.0K822.0K182.0K000
Income before tax-45.7M7.17M-42.5M-72.9M-30.6M-109.0M-92.9M-46.0M-21.1M-8.26M
Income tax0027.2M11.3M316.0K23.0K-9.58M1.88M-754.0K-5.00K
Net income-45.7M7.17M-61.3M-111.6M-30.6M-109.0M-92.9M-46.0M-21.1M-8.25M
Earnings per share, basic-3.561.05-15.96-38.10-0.52-2.09-2.21-2.92-18.81-0.49
Earnings per share, diluted-3.561.04-15.96-38.10-0.52-2.09-2.21-2.92

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents110.8M85.9M116.7M189.6M143.7M89.8M180.9M103.2M62.8M93.4M
Short-term investments4.76M413.0K0
Receivables0229.0K901.0K720.0K488.0K10.0M965.0K523.0K22.0K386.0K
Inventory7.55M17.4M5.76M9.50M
Current assets118.7M95.0M136.4M199.1M161.8M105.6M193.7M115.7M64.3M94.4M
Property, plant and equipment1.43M3.09M6.34M11.8M25.2M35.1M39.6M21.1M8.14M3.54M
Total assets154.4M136.4M159.8M238.2M211.5M150.2M235.2M138.6M72.7M98.4M
Accounts payable296.0K1.31M2.97M653.0K1.14M792.0K2.04M2.22M1.81M1.29M
Current liabilities8.91M15.0M50.0M59.7M36.0M42.8M26.9M14.1M9.20M8.34M
Long-term debt22.4M22.3M22.2M2.48M
Total debt28.8M30.0M31.3M22.2M2.48M10.5M
Total liabilities62.2M80.0M140.9M177.7M120.3M105.7M96.9M98.6M99.1M103.2M
Shareholders' equity92.2M56.4M18.9M60.4M91.2M44.4M138.3M40.0M-26.4M-4.75M
Shares outstanding24.1M8.20M4.16M3.70M60.9M52.7M51.2M15.9M1.12M16.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-65.8M-58.4M-84.1M-45.8M-10.9M-87.4M-71.0M-51.7M-24.2M92.3M
Capital spending-85.0K-250.0K-1.96M-3.32M-5.05M-5.03M-24.7M-14.3M-5.57M-2.08M
Free cash flow-65.9M-58.7M-86.1M-49.1M-15.9M-92.4M-95.7M-66.0M-29.7M90.2M
Cash from investing-634.0K-215.0K5.83M-3.32M-5.80M-5.03M-24.7M-15.7M-5.51M-2.08M
Cash from financing95.2M50.5M5.39M95.0M70.5M1.33M173.4M107.8M-937.0K-12.4M
Dividends paid-12.4M
Share buybacks74.7M67.3M689.0K136.4M0-952.0K49.0K
Change in cash28.7M-8.21M-72.9M45.9M53.9M-91.1M77.7M40.4M-30.6M77.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
8-K · Current reportNov 9, 2026Current reportSEC
144 · Notice of proposed saleNov 6, 2026Other filingsSEC
8-K · Current reportNov 6, 2026Current reportSEC
424B5 · ProspectusNov 5, 2026Offer documentSEC
144 · Notice of proposed saleNov 5, 2026Other filingsSEC
FWP · Free writing prospectusNov 5, 2026Offer documentSEC
8-K · Current reportNov 5, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 3, 2026Big-stake noticeSEC
8-K · Current reportNov 3, 2026ResultsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 24, 2026Big-stake noticeSEC
8-K · Current reportAug 24, 2026Current reportSEC
S-8 · Registration statement for employee plansAug 7, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
8-K · Current reportJul 27, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJul 20, 2026Big-stake noticeSEC
8-K · Current reportJul 1, 2026Current reportSEC
8-K · Current reportJun 16, 2026Material contractSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportMay 27, 2026Current reportSEC
8-K · Current reportMay 26, 2026Management or board changeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 15, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 8, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 8, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 27, 2026Meeting noticeSEC
8-K · Current reportMar 17, 2026Current reportSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 11, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 27, 2026Big-stake noticeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJan 22, 2026Big-stake noticeSEC
144 · Notice of proposed saleJan 21, 2026Other filingsSEC
144 · Notice of proposed saleJan 21, 2026Other filingsSEC
144 · Notice of proposed saleJan 21, 2026Other filingsSEC
8-K · Current reportJan 13, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveJan 8, 2026Other filingsSEC
CORRESP · Letter to the SECJan 5, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 2, 2026Other filingsSEC
S-3 · Registration statementDec 30, 2025Offer documentSEC
S-8 · Registration statement for employee plansDec 30, 2025Offer documentSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 12, 2025Current reportSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
FWP · Free writing prospectusNov 10, 2025Offer documentSEC
8-K · Current reportNov 10, 2025Current reportSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
10-Q · Quarterly reportNov 3, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025ResultsSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
8-K · Current reportSep 2, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
8-K · Current reportAug 6, 2025Current reportSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
144 · Notice of proposed saleJul 3, 2025Other filingsSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
8-K · Current reportJun 3, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 25, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 15, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 15, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 15, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 4, 2025Meeting noticeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMar 26, 2025Big-stake noticeSEC
424B5 · ProspectusMar 26, 2025Offer documentSEC
10-K · Annual reportMar 26, 2025Annual reportSEC
8-K · Current reportMar 26, 2025ResultsSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
144 · Notice of proposed saleMar 24, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMar 18, 2025Big-stake noticeSEC
8-K · Current reportMar 7, 2025Management or board changeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
144 · Notice of proposed saleMar 5, 2025Other filingsSEC
144 · Notice of proposed saleMar 4, 2025Other filingsSEC
144 · Notice of proposed saleMar 4, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportJan 29, 2025Management or board changeSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
144 · Notice of proposed saleJan 22, 2025Other filingsSEC
144 · Notice of proposed saleJan 22, 2025Other filingsSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
8-K · Current reportJan 8, 2025ResultsSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
144 · Notice of proposed saleNov 4, 2024Other filingsSEC
144 · Notice of proposed saleNov 4, 2024Other filingsSEC
10-Q · Quarterly reportNov 4, 2024Quarterly reportSEC
8-K · Current reportNov 4, 2024ResultsSEC
8-K · Current reportOct 24, 2024ResultsSEC
8-K · Current reportSep 12, 2024Management or board changeSEC
8-K · Current reportSep 3, 2024Current reportSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
S-8 · Registration statement for employee plansJul 1, 2024Offer documentSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
144 · Notice of proposed saleJun 10, 2024Other filingsSEC
144 · Notice of proposed saleJun 10, 2024Other filingsSEC
8-K · Current reportJun 10, 2024Management or board changeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC

This page holds 200 of 611 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Precision BioSciences, Inc.’s releases · as of Nov 16, 2026

Common shares
38,170,796
Fully diluted
38,249,088

Fully diluted

LineSharesAs of
Common shares38,170,796
Options and RSUs78,292Nov 16, 2026

Warrants and options

Lot
RSUs · expiry not stated
RSUs · expiry not stated

Share count over time

CountShares
Nov 22, 202638,170,796

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Lynx1 Capital Management LP2.76M9.9%US$17.3M+1.81MNov 16, 2026
abrdn2.23M8.0%US$14MNo changeNov 10, 2026
Bleichroeder LP2.02M7.2%US$12.6MNo changeNov 13, 2026
BlackRock1.61M5.8%US$10.1M+434KNov 13, 2026
Vanguard1.45M5.2%US$9.11M−637Nov 13, 2026
Boothbay Fund Management, LLC1.35M4.8%US$8.43MNo changeNov 16, 2026
Driehaus Capital Management LLC947K3.4%US$5.93MNo changeNov 16, 2026
Parkman Healthcare Partners LLC837K3.0%US$5.24MNewNov 16, 2026
Affinity Asset Advisors, LLC647K2.3%US$4.05MNo changeNov 13, 2026
Geode Capital634K2.3%US$3.97M+13,177Nov 6, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
ArrowMark Colorado Holdings LLC454K1.6%US$2.84M+180KNov 16, 2026
State Street434K1.6%US$2.72M+7,138Nov 12, 2026
Octagon Capital Advisors LP430K1.5%US$2.69M−920KNov 16, 2026
Schonfeld Strategic Advisors LLC274K0.98%US$1.72MNewNov 16, 2026
Two Sigma246K0.88%US$1.54M+8,630Nov 16, 2026
Mackenzie236K0.84%US$1.48M−245KNov 2, 2026
Corient Private Wealth LP235K0.84%US$1.47M−10,000Nov 16, 2026
Northern Trust191K0.68%US$1.19M+676Nov 16, 2026
Fidelity165K0.59%US$1.03M+165KNov 10, 2026
Marshall Wace, LLP162K0.58%US$1.02MNewNov 13, 2026
Acadian Asset Management LLC137K0.49%US$853K−169KNov 9, 2026
Goldman Sachs128K0.46%US$803K−11,586Nov 16, 2026
Commonwealth Equity Services, LLC117K0.42%US$733K+1,165Nov 2, 2026
Quarry LP113K0.40%US$708K+15,119Nov 16, 2026
Empery Asset Management, LP102K0.37%US$640K−674KNov 16, 2026
Dimensional97,9410.35%US$613K+11,480Nov 4, 2026
UBS94,9050.34%US$594K+36,206Nov 16, 2026
Morgan Stanley92,0130.33%US$576K−38,523Nov 13, 2026
BFC Planning, Inc.85,0000.30%US$532K+18,000Nov 13, 2026
Russell Investments Group, Ltd.82,8180.30%US$518K+80,900Nov 6, 2026
Susquehanna79,8090.29%US$500K+22,503Nov 16, 2026
Schwab78,3270.28%US$490KNo changeNov 16, 2026
Renaissance Technologies76,2630.27%US$477K+7,686Nov 12, 2026
AQR Capital Management LLC67,5110.24%US$423KNewNov 16, 2026
Citadel60,5980.22%US$379K−7,954Nov 16, 2026
BNY59,3870.21%US$372KNo changeNov 5, 2026
Jump Financial, LLC43,6000.16%US$273K−23,200Nov 13, 2026
Velan Capital Investment Management LP40,0000.14%US$250KNo changeNov 16, 2026
American Century36,6880.13%US$230K+17,311Nov 20, 2026
Barclays34,2200.12%US$214K+22,898Nov 6, 2026
Nuveen32,2950.12%US$202K+8Nov 10, 2026
Point72 Asset Management, L.P.31,2780.11%US$196K+17,174Nov 16, 2026
Squarepoint Ops LLC30,0640.11%US$188K−107KNov 9, 2026
Invesco27,2950.10%US$171K−287Nov 12, 2026
Rhumbline Advisers27,1780.10%US$170K−686Nov 10, 2026
Engineers Gate Manager LP26,7000.10%US$167K+5,800Nov 16, 2026
Bank of America25,1780.09%US$158K−8,129Nov 16, 2026
LPL Financial LLC25,0060.09%US$157K−4,000Nov 6, 2026
Connor, Clark & Lunn Investment Management Ltd.21,2070.08%US$133K+7,136Nov 10, 2026
BNP Paribas20,9120.07%US$131K+13,370Nov 12, 2026

This page holds 50 of 104 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund778K2.8%US$6.12M+149KJun 30, 2026
iShares Russell 2000 ETF427K1.5%US$3.36MNewJun 30, 2026
Vanguard Extended Market Index Fund312K1.1%US$2.46M+47,423Jun 30, 2026
Meridian Contrarian Fund274K0.98%US$2.15M+95,000Jun 30, 2026
Fidelity Small Cap Index Fund262K0.94%US$1.83MNewJul 31, 2026
iShares Russell 2000 Value ETF168K0.60%US$1.32MNewJun 30, 2026
Fidelity Extended Market Index Fund127K0.45%US$883K+5,046May 31, 2026
iShares Micro-Cap ETF75,8000.27%US$596K+23,544Jun 30, 2026
JPMorgan U.S. Small Company Fund61,0760.22%US$480KNewJun 30, 2026
Schwab Small-Cap Index Fund58,3270.21%US$408KNewJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Jacob Discovery Fund52,0890.19%US$363K+5,000May 31, 2026
Fidelity Total Market Index Fund48,5620.17%US$338K+15,761May 31, 2026
Fidelity Series Total Market Index Fund37,4960.13%US$261K+7,261May 31, 2026
Master Small Cap Index Series34,1750.12%US$269KNewJun 30, 2026
Fidelity Small Cap Value Index Fund33,5660.12%US$264KNewJun 30, 2026
Nuveen Small Cap Blend Index Fund32,2870.12%US$226KNewJul 31, 2026
U.S. Small Cap Equity Fund22,7230.08%US$159KNewJul 31, 2026
Dimensional U.S. Small Cap ETF20,8080.07%US$145K+11,794Jul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund20,4620.07%US$143KNewJul 31, 2026
Schwab Total Stock Market Index Fund20,0000.07%US$140KNo changeJul 31, 2026
EQ/2000 Managed Volatility Portfolio19,3050.07%US$152KNewJun 30, 2026
LVIP State Street Small-Cap Index Fund18,2000.07%US$143KNewJun 30, 2026
U.S. Micro Cap Portfolio16,8870.06%US$118K+15,487Jul 31, 2026
Fidelity Nasdaq Composite Index Fund15,6210.06%US$109K+12,964May 31, 2026
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund15,4630.06%US$122KNewJun 30, 2026
NVIT GS Small Cap Equity Insights Fund14,6450.05%US$115KNewJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund13,7300.05%US$108K+9,278Jun 30, 2026
LVIP JPMorgan Small Cap Core Fund13,2150.05%US$104KNewJun 30, 2026
Small Cap Index Fund12,5470.04%US$98,619NewJun 30, 2026
Vanguard Balanced Index Fund12,0040.04%US$94,351No changeJun 30, 2026
Global X Russell 2000 ETF11,4710.04%US$80,182NewJul 31, 2026
Avantis U.S. Small Cap Equity ETF10,6040.04%US$73,910NewMay 31, 2026
Vy(R) Jpmorgan Small Cap Core Equity Portfolio8,7130.03%US$68,484NewJun 30, 2026
MetLife Russell 2000 Index Portfolio8,2480.03%US$64,829NewJun 30, 2026
Small-Cap Index Portfolio6,6990.02%US$52,654NewJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio6,4000.02%US$50,304NewJun 30, 2026
Dimensional U.S. Core Equity 2 ETF5,8260.02%US$40,724NewJul 31, 2026
iShares Russell Small/Mid-Cap Index Fund5,7630.02%US$40,283NewJul 31, 2026
Small Cap Index Trust5,6600.02%US$44,488NewJun 30, 2026
U.S. Small Cap Portfolio5,3990.02%US$37,739NewJul 31, 2026
NVIT Small Cap Index Fund5,2130.02%US$40,974NewJun 30, 2026
1290 VT Micro Cap Portfolio4,9960.02%US$39,269+1,383Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio4,0350.01%US$31,715NewJun 30, 2026
DWS Small Cap Index VIP3,7530.01%US$29,499NewJun 30, 2026
U.S. Vector Equity Portfolio3,6730.01%US$25,674NewJul 31, 2026
T. Rowe Price Small-Cap Index Fund3,6590.01%US$28,760NewJun 30, 2026
EQ/AB Small Cap Growth Portfolio3,5100.01%US$27,589NewJun 30, 2026
EQ/Small Company Index Portfolio3,5100.01%US$27,589NewJun 30, 2026
Dimensional US Core Equity 1 ETF2,9470.01%US$20,600NewJul 31, 2026
Voya RussellTM Small Cap Index Portfolio2,9000.01%US$22,794NewJun 30, 2026

This page holds 50 of 79 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Scimeca Dario
Officer: Chief Legal Officer
Sale2,821USD 9.75US$27,505Nov 10, 2026
Frankel Stanley
Director
Buy1,000USD 6.00US$6,000Sep 28, 2026
Germano Geno J
Director
Buy2,609USD 6.28US$16,385Sep 25, 2026
Brown Melinda
Director
Buy1,135USD 6.27US$7,116Sep 25, 2026

Big stakes

HolderStakeSharesDate
Lynx1 Capital Management LP9.90%2.76MSep 30, 2026
Matthew Smith9.40%1.12MJun 30, 2025
Aberdeen Group plc8.88%2.14MDec 31, 2025
Bleichroeder LP8.21%1.9MDec 31, 2025
Octagon Capital Advisors LP5.73%1.65MSep 30, 2026
BlackRock, Inc.5.01%1.38MSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Shalini Sharp
Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Sutro Biopharma, Inc. (Director · Nov 8, 2018 – Jun 6, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past); Agenus Inc. (Director · Oct 1, 2006 – Mar 2, 2018 · Past)
Director · Mar 27, 2019 – May 10, 2021 · Past
Geno Germano
Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Entera Bio Ltd. (Chairman of the Board · Since at least Feb 4, 2026); Sage Therapeutics Inc (Director · Since at least Jun 6, 2018); Bioverativ Inc (Director · Jan 31, 2018 – Mar 8, 2018 · Past); The Medicines Company (Director · Nov 9, 2017 – Jan 6, 2020 · Past)
Director · Since at least Mar 10, 2020
Robert J Adelman
Other companies: Metacrine Inc (Director · Sep 15, 2020 – Sep 18, 2020 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 14, 2008 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past)
Director · Mar 27, 2019 – Apr 1, 2019 · Past
Alan F. List
Other companies: TuHURA Biosciences, Inc. (Director · Since at least Oct 18, 2024)
Chief Medical Officer · Apr 26, 2021 – May 1, 2024 · Past
Christopher Heery
Other companies: Arcellx Inc (CHIEF MEDICAL OFFICER · Since at least Feb 3, 2022)
Chief Medical Officer · Sep 30, 2019 – Jun 8, 2020 · Past
John Alexander Kelly
Other companies: Forest Laboratories Inc (SVP - Chief Comm's & IR · Oct 24, 2013 – Jun 30, 2014 · Past)
Chief Financial Officer · Since at least Jan 1, 2021
Melinda Brown
Other companies: Tapestry, Inc. (SVP, Controller and PAO · Aug 20, 2016 – Aug 17, 2018 · Past)
Director · Since at least May 26, 2022
Michael Amoroso
Other companies: Abeona Therapeutics Inc. (Director · Since at least Oct 26, 2020)
President, Chief Executive Officer · Since at least Oct 15, 2021
Raymond F Schinazi
Other companies: Cocrystal Pharma, Inc. (Director · Nov 25, 2014 – Sep 21, 2018 · Past)
Director · Mar 27, 2019 – May 10, 2022 · Past
Samuel C Wadsworth
Other companies: Dimension Therapeutics (Chief Scientific Officer · Oct 21, 2015 – Nov 7, 2017 · Past)
Director · Nov 8, 2021 – Jun 4, 2024 · Past
All 32 people
PersonSeat
Shane Barton
Other companies: BioAge Labs, Inc. (SVP, Finance · Since at least Sep 25, 2024)
VP & Corporate Controller · Jan 1, 2021 – Jun 7, 2023 · Past
Tony Dung Ling Yao
Other companies: 4D Molecular Therapeutics, Inc. (Director · Dec 10, 2020 – Dec 15, 2020 · Past)
Director · Mar 27, 2019 – Apr 3, 2019 · Past
Abid AnsariChief Financial Officer · Mar 27, 2019 – Jun 15, 2020 · Past
Alex KellyChief Operating Officer · Since at least Aug 6, 2026
Cassandra Louise GorsuchChief Scientific Officer · Since at least Aug 1, 2026
Cassie GorsuchChief Scientific Officer · Since at least Aug 6, 2026
Cindy AtwellChief Development Officer · Since at least Jul 27, 2026
Dario ScimecaChief Legal Officer · Since at least Jun 10, 2019
David S ThomsonChief Operating Officer · Mar 27, 2019 – Jun 23, 2021 · Past
Derek JantzChief Scientific Officer, Director · Mar 27, 2019 – Jun 7, 2022 · Past
Fayaz KhaziCEO of Elo Life Systems · Mar 27, 2019 – Jun 7, 2021 · Past
Jeff SmithChief Research Officer · Since at least Oct 8, 2026
J Jefferson SmithChief Research Officer · Since at least Sep 1, 2022
Juli BlancheChief People Officer · Since at least Nov 5, 2026
Kevin BuehlerDirector · Since at least Nov 8, 2019
Mark SulkowskiHead Clinical Development Advisor · Since at least Oct 8, 2026
Matthew R KanePresident and CEO, Director · Sep 23, 2019 – Jun 7, 2021 · Past
Mei Zhang Lu BurrisChielf Accounting Officer · Since at least Aug 1, 2026
Naresh TannaChief Financial Officer · Since at least Aug 1, 2026
Neil LeatherburySenior Vice President of Chemistry, Manufacturing, and Controls (CMC) · Since at least Oct 8, 2026
Shari Lisa PiréDirector · Since at least Nov 8, 2021
Stanley FrankelDirector · Since at least Apr 12, 2021

Open People

Log in to ask 6ix AI your own questions about Precision BioSciences, Inc.